ReviewClinical interventions in aging2022
Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects.
Review in Clinical interventions in aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Mitochondrial Epigenetic Alterations Induced by Biomass Smoke Exposure and Their Role in Age-Related Breast Cancer Risk: A Machine Learning-Based Predictive Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Review
- Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.Clinical breast cancer · 2025Article
- Age-dependent differences in breast tumor microenvironment: challenges and opportunities for efficacy studies in preclinical models.Cell death and differentiation · 2025Article
- Article
- Article
- Review
- Effects of a Multimodal Program on Frailty Syndrome and Psychological Alterations in Breast Cancer Women Treated with Aromatase Inhibitors.Clinics and practice · 2025Article
- The role of workplace support systems in reducing anxiety among cancer-diagnosed workers across disciplines in Jordanian oncology settings.Palliative care and social practice · 2025Article
- Mastectomy, HER2 Receptor Positivity, NPI, Late Stage and Luminal B-Type Tumor as Poor Prognostic Factors in Geriatric Patients with Breast Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Molecular classification of geriatric breast cancer displays distinct senescent subgroups of prognostic significance.Molecular therapy. Nucleic acids · 2024Article
- Impact of a Physical Exercise and Health Education Program on Metabolic Syndrome and Quality of Life in Postmenopausal Breast Cancer Women Undergoing Adjuvant Treatment with Aromatase Inhibitors.Medicina (Kaunas, Lithuania) · 2024Article
- Evaluation of histopathological findings in very old people (≥ 80 years old) in Turkish population.BMC geriatrics · 2024Article
- Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.NPJ breast cancer · 2024Article
- Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Observational
- Deep learning-guided adjuvant chemotherapy selection for elderly patients with breast cancer.Breast cancer research and treatment · 2024Article
- Multicenter Study on Breast Cancer in the Geriatric Population: Insights for Effective Treatment Strategies.Cureus · 2024Article
- The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions.Journal of clinical medicine · 2023Review
- Anticholinergic burden risk and prevalence of medications carrying anticholinergic properties in elderly cancer patients in Jordan.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer diagnosed among women worldwide and more than half are diagnosed above the age of 60 years. Life expectancy is increasing and the number of breast cancer cases diagnosed among older women are expected to increase. Undertreatment, mostly due to unjustifiable fears of advanced-age and associated comorbidities, is commonly practiced in this group of patients who are under-represented in clinical trials and their management is not properly addressed in clinical practice guidelines. With modern surgery and anesthesia, breast surgeries are considered safe and is usually associated with very low complication rates, regardless of extent of surgery. However, oncoplastic surgery and management of the axilla can be tailored based on patients'- and disease-related factors. Most of chemotherapeutic agents, along with targeted therapy and anti-Human epidermal growth factor receptor-2 (HER2) drugs can be safely given for older patients, however, dose adjustment and close monitoring of potential adverse events might be needed. The recently introduced cyclin-D kinase (CDK) 4/6-inhibitors in combination with aromatase inhibitors (AI) or fulvestrant, which changed the landscape of breast cancer therapy, are both safe and effective in older patients and had substituted more aggressive and potentially toxic interventions. Despite its proven efficacy, adjusting or even omitting adjuvant radiation therapy, at least in low-risk older patients, is safe and frequently practiced. In this paper, we review existing data related to breast cancer management among older patients across the continuum; from resection of the primary tumor through adjuvant chemotherapy, radiation and endocrine therapy up to the management of recurrent and advanced-stage disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.